13C5-adenosine production with ex vivo alkaline phosphatase supplementation. by Jesse A. Davidson (3158913)

Differential gene expression in Huh-7 cells and PHH resulting from treatment with THR agonists. by Xuan G. Luong (9761423)

Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study by Asita Wongprikorn (2837378)

“…<div><p>Background</p><p>Dyslipidemia as a risk factor of cardiovascular disease is common especially in HIV-infected patients who are using protease inhibitors (PIs) including atazanavir. …”

The effect of MDA and GSH Content of HT22 cells (A, B) and PC12 cells (C, D). by Chunxia Chen (134627)

The effect of HBO on ROS of HT22 cells (A, C) and PC12 cells (B, D) (200×). by Chunxia Chen (134627)

S4 Fig - by R. J. S. D. Heine (17889199)

“…In the scenario analysis the profit margin contributed most to a higher CBPs for both drugs. Lower estimates resulted from assumed lower R&D costs.…”

S1 Fig - by R. J. S. D. Heine (17889199)

“…In the scenario analysis the profit margin contributed most to a higher CBPs for both drugs. Lower estimates resulted from assumed lower R&D costs.…”

S5 Fig - by R. J. S. D. Heine (17889199)

“…In the scenario analysis the profit margin contributed most to a higher CBPs for both drugs. Lower estimates resulted from assumed lower R&D costs.…”

S3 Fig - by R. J. S. D. Heine (17889199)

“…In the scenario analysis the profit margin contributed most to a higher CBPs for both drugs. Lower estimates resulted from assumed lower R&D costs.…”

S6 Fig - by R. J. S. D. Heine (17889199)

“…In the scenario analysis the profit margin contributed most to a higher CBPs for both drugs. Lower estimates resulted from assumed lower R&D costs.…”

Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

“…In the scenario analysis the profit margin contributed most to a higher CBPs for both drugs. Lower estimates resulted from assumed lower R&D costs.…”

S2 Fig - by R. J. S. D. Heine (17889199)

“…In the scenario analysis the profit margin contributed most to a higher CBPs for both drugs. Lower estimates resulted from assumed lower R&D costs.…”

S1 Data - by R. J. S. D. Heine (17889199)

“…In the scenario analysis the profit margin contributed most to a higher CBPs for both drugs. Lower estimates resulted from assumed lower R&D costs.…”

CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

Implementation of indication-based pricing (10^th scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

Sequential viral infection modulates the intestinal bacterial microbiome. by Yuhao Li (1559569)

Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

S1 Fig - by Asadollahi Parisa (8837432)

Macroscopic and histological assessment of colic tumor and inflammation in mice. by Asadollahi Parisa (8837432)